Neuroscience & Neurological Disorders

Biography

Lucie Bruijn, Ph.D. MBA joined The ALS Association in January 2001 as Science Director and Vice President and is currently Chief Scientist for the organization. Prior to that Dr. Bruijn led a team of researchers in drug discovery programs for Parkinson and Alzheimer disease at Bristol Myers Squibb. She has served as a member of the National Institute of Neurological Disorders and Stroke (NINDS) advisory council. She is the former chair and current member of the integration panel of the Department of Defense (DOD) for the ALS Research Program supporting translational research for ALS and has served on the Data Safety and Monitoring Board for the Neuralstem trial, the first US stem cell trial for ALS. Dr. Lucie Bruijn continues to publish in peer-reviewed journals and attends scientific meetings throughout the year to ensure that the research portfolio maximizes opportunities in the field. In her role on the Scientific Advisory Board of Prize4Life. Dr. Lucie Bruijn has been engaged in developing one of the first Prize concepts for ALS bringing new players into the field. Most recently she has developed an Assistive Technology Prize for communications and a PET Tracer Challenge for TDP43, an abnormally accumulated protein present in ALS and other neurological disorders. These incentives have spurred significant interest from diverse expertise including imaging, biotechnology and bioengineering.

Research Interest

Dr. Lucie Bruijn leads a global research effort at the ALS Association. She has expanded on the existing TREAT ALS portfolio to include large international collaborative initiatives in drug development and precision medicine.